Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw strong trading volume on Friday . 51,696 shares traded hands during trading, an increase of 83% from the previous session's volume of 28,224 shares.The stock last traded at $16.10 and had previously closed at $15.99.
Wall Street Analysts Forecast Growth
TLX has been the topic of a number of research reports. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, March 12th.
View Our Latest Stock Analysis on TLX
Telix Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The company has a 50-day moving average of $17.04 and a two-hundred day moving average of $16.94.
Institutional Investors Weigh In On Telix Pharmaceuticals
An institutional investor recently bought a new position in Telix Pharmaceuticals stock. ABC Arbitrage SA bought a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 26,939 shares of the company's stock, valued at approximately $451,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
